<p>Truist Financial 在週二發佈的研究報告中開始覆蓋 Dianthus Therapeutics（NASDAQ:DNTH - 獲取免費報告）的股票，Briefing.com 自動導入報道。該券商對該股票設定了 “買入” 評級和 56.00 美元的目標價。Truist Financial 的目標價表明該公司當前價格有 62.70% 的潛在上漲空間。</p>
<p>獲取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
<p>其他股票分析師也對該公司發佈了研究報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Dianthus Therapeutics 股票的 “賣出（d-）” 評級。Guggenheim 將 Dianthus Therapeutics 的目標價從 92.00 美元上調至 100.00 美元，並在 9 月 9 日的研究報告中給予該股票 “買入” 評級。Stifel Nicolaus 將 Dianthus Therapeutics 的目標價從 52.00 美元上調至 65.00 美元，並在 9 月 12 日的研究報告中給予該股票 “買入” 評級。William Blair 在 7 月 2 日的研究報告中開始覆蓋 Dianthus Therapeutics，並對該公司給予了 “跑贏大盤” 的評級。最後，HC Wainwright 在 9 月 8 日的研究報告中重申了 “買入” 評級，並對 Dianthus Therapeutics 股票設定了 40.00 美元的目標價。十位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 60.88 美元。</p>
<p><strong>查看我們關於 Dianthus Therapeutics 的最新研究報告</strong></p>
<h2>Dianthus Therapeutics 股票表現</h2>
<p>NASDAQ:DNTH 週二開盤價為 34.42 美元。該股票的 50 日簡單移動平均線為 29.81 美元，200 日簡單移動平均線為 22.83 美元。Dianthus Therapeutics 的 52 周低點為 13.36 美元，52 周高點為 40.16 美元。該公司的市值為 11.1 億美元，市盈率為-10.59，貝塔值為 1.58。</p>
<p>Dianthus Therapeutics（NASDAQ:DNTH - 獲取免費報告）最近於 8 月 7 日發佈了季度財報。該公司報告每股收益（EPS）為-0.88 美元，低於市場共識預期的-0.86 美元，差距為-0.02 美元。該公司本季度的收入為 19 萬美元，而市場共識預期為 87 萬美元。Dianthus Therapeutics 的淨利潤率為-2364.56%，股本回報率為-34.72%。股票分析師預測 Dianthus Therapeutics 本財年的每股收益將為-2.61 美元。</p>
<h2>內部活動</h2>
<p>在其他消息中，首席財務官 Ryan Savitz 於 9 月 9 日出售了 20,000 股該公司的股票。該股票以 35.00 美元的平均價格出售，總價值為 700,000.00 美元。該交易已在提交給證券交易委員會的文件中披露，您可以通過此超鏈接訪問。16.56% 的股票由內部人士持有。</p>
<h2>機構投資者對 Dianthus Therapeutics 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對該公司的持股。ADAR1 Capital Management LLC 在第一季度將其在 Dianthus Therapeutics 的持股增加了 3.4%。ADAR1 Capital Management LLC 目前擁有 18,285 股該公司的股票，價值 332,000 美元，此前在該期間內又購買了 602 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Dianthus Therapeutics 的持股增加了 4.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 15,334 股該公司的股票，價值 280,000 美元，此前在該期間內又購買了 618 股。紐約梅隆銀行在第一季度將其在 Dianthus Therapeutics 的持股增加了 1.0%。紐約梅隆銀行目前擁有 73,638 股該公司的股票，價值 1,336,000 美元，此前在該期間內又購買了 748 股。Charles Schwab Investment Management Inc. 在第一季度將其在 Dianthus Therapeutics 的持股增加了 0.6%。Charles Schwab Investment Management Inc. 目前擁有 168,102 股該公司的股票，價值 3,049,000 美元，此前在該期間內又購買了 1,081 股。最後，Raymond James Financial Inc. 在第二季度購買了 Dianthus Therapeutics 的新股份，價值約 27,000 美元。目前 47.53% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Dianthus Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Dianthus Therapeutics, Inc. 是一家臨牀階段的生物技術公司，開發針對嚴重自身免疫和炎症疾病的補體治療。該公司正在開發 DNTH103，這是一種單克隆抗體，目前處於第二階段臨牀試驗中，旨在治療廣泛性重症肌無力、多發性運動神經病和慢性炎症脱髓鞘多神經病。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Dianthus Therapeutics</li>
<li>商業服務股票投資</li>
<li>Fastenal 股票在十月回調——現在是購買 FAST 的時機嗎？</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>為什麼國會在財報前購買 Intuitive Surgical</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>FICO 的大幅下跌可能是今年最佳購買機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Dianthus Therapeutics 嗎？</h2>
<p>在考慮 Dianthus Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議他們現在購買，以便在更廣泛的市場注意到之前……而 Dianthus Therapeutics 並不在名單上。</p>
<p>雖然 Dianthus Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DNTH

<p>Truist Financial 已經開始覆蓋 Dianthus Therapeutics (NASDAQ:DNTH)，給予 “買入” 評級，並設定目標價為 56.00 美元，表示潛在上漲空間為 62.70%。其他分析師的意見各不相同，Weiss Ratings 給出了 “賣出” 評級，而 Guggenheim 和 Stifel Nicolaus 分別設定了更高的目標價 100.00 美元和 65.00 美元。該股票目前交易價格為 34.42 美元，平均評級為 “適度買入”，目標價為 60.88 美元。Dianthus 是一家專注於自身免疫疾病治療的臨牀階段生物技術公司</p>

<p>Truist Financial began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a &#34;buy&#34; rating and a $56.00 price target on the stock. Truist Financial's target price indicates a potential upside of 62.70% from the company's current price.</p>
<div class="lb-trans"><p>Truist Financial 在週二發佈的研究報告中開始覆蓋 Dianthus Therapeutics（NASDAQ:DNTH - 獲取免費報告）的股票，Briefing.com 自動導入報道。該券商對該股票設定了 “買入” 評級和 56.00 美元的目標價。Truist Financial 的目標價表明該公司當前價格有 62.70% 的潛在上漲空間。</p>
</div><p>Get <strong>Dianthus Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
</div><p>Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Guggenheim upped their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, September 12th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an &#34;outperform&#34; rating for the company. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, September 8th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $60.88.</p>
<div class="lb-trans"><p>其他股票分析師也對該公司發佈了研究報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Dianthus Therapeutics 股票的 “賣出（d-）” 評級。Guggenheim 將 Dianthus Therapeutics 的目標價從 92.00 美元上調至 100.00 美元，並在 9 月 9 日的研究報告中給予該股票 “買入” 評級。Stifel Nicolaus 將 Dianthus Therapeutics 的目標價從 52.00 美元上調至 65.00 美元，並在 9 月 12 日的研究報告中給予該股票 “買入” 評級。William Blair 在 7 月 2 日的研究報告中開始覆蓋 Dianthus Therapeutics，並對該公司給予了 “跑贏大盤” 的評級。最後，HC Wainwright 在 9 月 8 日的研究報告中重申了 “買入” 評級，並對 Dianthus Therapeutics 股票設定了 40.00 美元的目標價。十位分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 60.88 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Dianthus Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Dianthus Therapeutics 的最新研究報告</strong></p>
</div><h2>Dianthus Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Dianthus Therapeutics 股票表現</h2>
</div><p>NASDAQ:DNTH opened at $34.42 on Tuesday. The stock has a 50-day simple moving average of $29.81 and a two-hundred day simple moving average of $22.83. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $40.16. The firm has a market capitalization of $1.11 billion, a PE ratio of -10.59 and a beta of 1.58.</p>
<div class="lb-trans"><p>NASDAQ:DNTH 週二開盤價為 34.42 美元。該股票的 50 日簡單移動平均線為 29.81 美元，200 日簡單移動平均線為 22.83 美元。Dianthus Therapeutics 的 52 周低點為 13.36 美元，52 周高點為 40.16 美元。該公司的市值為 11.1 億美元，市盈率為-10.59，貝塔值為 1.58。</p>
</div><p>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Equities analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Dianthus Therapeutics（NASDAQ:DNTH - 獲取免費報告）最近於 8 月 7 日發佈了季度財報。該公司報告每股收益（EPS）為-0.88 美元，低於市場共識預期的-0.86 美元，差距為-0.02 美元。該公司本季度的收入為 19 萬美元，而市場共識預期為 87 萬美元。Dianthus Therapeutics 的淨利潤率為-2364.56%，股本回報率為-34.72%。股票分析師預測 Dianthus Therapeutics 本財年的每股收益將為-2.61 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 16.56% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席財務官 Ryan Savitz 於 9 月 9 日出售了 20,000 股該公司的股票。該股票以 35.00 美元的平均價格出售，總價值為 700,000.00 美元。該交易已在提交給證券交易委員會的文件中披露，您可以通過此超鏈接訪問。16.56% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Dianthus Therapeutics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC raised its holdings in shares of Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after buying an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after buying an additional 618 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Dianthus Therapeutics by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after buying an additional 748 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock worth $3,049,000 after buying an additional 1,081 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對該公司的持股。ADAR1 Capital Management LLC 在第一季度將其在 Dianthus Therapeutics 的持股增加了 3.4%。ADAR1 Capital Management LLC 目前擁有 18,285 股該公司的股票，價值 332,000 美元，此前在該期間內又購買了 602 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Dianthus Therapeutics 的持股增加了 4.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 15,334 股該公司的股票，價值 280,000 美元，此前在該期間內又購買了 618 股。紐約梅隆銀行在第一季度將其在 Dianthus Therapeutics 的持股增加了 1.0%。紐約梅隆銀行目前擁有 73,638 股該公司的股票，價值 1,336,000 美元，此前在該期間內又購買了 748 股。Charles Schwab Investment Management Inc. 在第一季度將其在 Dianthus Therapeutics 的持股增加了 0.6%。Charles Schwab Investment Management Inc. 目前擁有 168,102 股該公司的股票，價值 3,049,000 美元，此前在該期間內又購買了 1,081 股。最後，Raymond James Financial Inc. 在第二季度購買了 Dianthus Therapeutics 的新股份，價值約 27,000 美元。目前 47.53% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>關於 Dianthus Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.</p>
<div class="lb-trans"><p>Dianthus Therapeutics, Inc. 是一家臨牀階段的生物技術公司，開發針對嚴重自身免疫和炎症疾病的補體治療。該公司正在開發 DNTH103，這是一種單克隆抗體，目前處於第二階段臨牀試驗中，旨在治療廣泛性重症肌無力、多發性運動神經病和慢性炎症脱髓鞘多神經病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Dianthus Therapeutics</li>
<li>Business Services Stocks Investing</li>
<li>Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>Why Congress Is Buying Intuitive Surgical Ahead of Earnings</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>FICO’s Big Dip Could Be the Best Buying Chance of the Year</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Dianthus Therapeutics</li>
<li>商業服務股票投資</li>
<li>Fastenal 股票在十月回調——現在是購買 FAST 的時機嗎？</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>為什麼國會在財報前購買 Intuitive Surgical</li>
<li>三隻超市股票證明它們仍然是必需品</li>
<li>FICO 的大幅下跌可能是今年最佳購買機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=DNTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Dianthus Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Dianthus Therapeutics 嗎？</h2>
</div><p>Before you consider Dianthus Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Dianthus Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議他們現在購買，以便在更廣泛的市場注意到之前……而 Dianthus Therapeutics 並不在名單上。</p>
</div><p>While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Dianthus Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Dianthus Therapeutics（NASDAQ:DNTH）被 Truist Financial 的分析師給予買入評級